The target compound (Z)-4-[3-(4-methyl-1,2,3-thiadiazol-5-yl)-3-(4-trifluoromethylphenyl)acr- yloyl]morpholine was synthesized by the nucleophilic substitution, Horner-Emmons reaction, ester hydrolysis, and condensation. Its structure was characterized by NMR, H RMS and single-crystal X-ray diffraction. The crystal of the target compound belongs to monoclinic system, space group P2₁ with a = 11.5058(15), b = 6.6626(10), c = 23.184(3) Å, V = 1777.3(4) ų, Z = 8, D_c = 1.496 Mg/m³, F(000) = 792 and μ = 0.229 mm^–1. X-ray analysis indicated C–H×××O intermolecular H-bonds in this crystal structure. The target compound exhibited 53% curative activity against TMV.